127-40-2Relevant academic research and scientific papers
NANOEMULSIONS HAVING REVERSIBLE CONTINUOUS AND DISPERSED PHASES
-
, (2017/08/01)
A nanoemulsion having reversible continuous and dispersed phases. The nanoemulsion includes an aqueous phase and an oil phase, a weight ratio of the aqueous phase to the oil phase being 1:40-100:1. In the nanoemulsion, the aqueous phase is dispersed as nanosized droplets in the oil phase or the oil phase is dispersed as nanosized droplets in the aqueous phase. The aqueous phase contains water or a water solution and a water-soluble organic nanostructure stabilizer. The oil phase contains an oil or an oil solution, an organic gel thickener, and a hydrophilic surfactant having a hydrophilic-lipophilic balance value greater than 8.0. Also disclosed is a method for preparing the above-described nanoemulsion.
Combination of carotenoids and epi-lutein
-
Page/Page column 18, (2018/01/20)
The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases.
Process for Synthesis of (3R,3'R,6'R)-Lutein and its Stereoisomers
-
Page/Page column 10-11; 24-25, (2009/10/30)
(3R,3′R,6′R)-Lutein and (3R,3′R)-zeaxanthin are two dietary carotenoids that are present in most fruits and vegetables commonly consumed in the US. These carotenoids accumulate in the human plasma, major organs, and ocular tissues. In the past decade, numerous epidemiological and experimental studies have shown that lutein and zeaxanthin play an important role in the prevention of age-related macular degeneration (AMD) that is the leading cause of blindness in the U.S. and Western World. The invention provides a process for the synthesis of (3R,3′R,6′R)-lutein and its stereoisomers from commercially available (rac)-α-ionone by a C15+C10+C15 coupling strategy. In addition, the present invention also provides access to the precursors of optically active carotenoids with 3-hydroxy-ε-end group that are otherwise difficult to synthesize. The process developed for the synthesis of lutein and its stereoisomers is straightforward and has potential for commercialization.
Total synthesis of (3R,3′R,6′R)-lutein and its stereoisomers
Khachik, Frederick,Chang, An-Ni
experimental part, p. 3875 - 3885 (2009/10/14)
(Chemical Equation Presented) (3R,3′R,6′R)-Lutein (1) is a major dietary carotenoid that is abundant in most fruits and vegetables commonly consumed in the U.S. and that accumulates in the human plasma, major organs, and ocular tissues. Numerous epidemiol
NUTRITIONAL FORMULATION
-
, (2009/09/08)
The present invention relates to nutritional supplements that provide an adult with essential vitamins and minerals that may be lacking in the adult's diet and prevent chronic diseases, such as osteoporosis. A number of combinations of nutrients in set ratios are provided to increase the body's ability to absorb and use the nutrients. These combinations are important in helping the body reach the proper balance required for maximized function. Because adults over the age of 50 years have different nutritional needs, nutritional supplements specifically designed for them are also provided.
METHOD OF RECOVERING XANTHOPHYLL
-
, (2008/06/13)
The present invention provides a method for collecting xanthophylls, the method comprising an adsorption step of contacting a sample containing xanthophylls with a hydrophilic resin to allow the resin to adsorb the xanthophylls; and a desorption step of eluting the xanthophylls adsorbed to the resin with a polar solvent. Preferably, the method comprises a step of washing the resin between the adsorption step and the desorption step. As the resin, a hydrophilic, acrylic and/or methacrylic resin is preferably used.
ISOLATION AND PURIFICATION OF CAROTENOIDS FROM MARIGOLD FLOWERS
-
Page/Page column 10-12, (2008/06/13)
The present invention explains a realistic and effective process for isolating and purifying carotenoids containing higher concentrations of carotenoids such as trans-lutein, trans-zeaxanthin, Cis-lutein, ?-carotene and Cryptoxanthin from Marigold flower petals under controlled conditions leaving no traces of any organic hazardous solvents. The process involves ensilaging marigold flowers, dehydration, solvent extraction, alkali hydrolysis of carotenoid esters with absolute alcohol, crystallization/purification using water, absolute alcohol mixture followed by filteration and drying until the crystals are considerably free from moisture and absolutely free from residual hazardous solvents. These crystals are suitable for nutraceutical and food products as supplements.
A PROCESS FOR ISOLATING, PURIFYING AND FORMULATING A STABLE, COMMERCIAL GRADE LUTEIN PASTE FROM OLEORESIN
-
Page/Page column 11-12, (2008/06/13)
The present invention relates to a process for obtaining stabilized Lutein with about 95% yield from oleoresin at ambient temperature, said process comprising steps of dissolving cleaned oleoresin in alcohol to obtain dissolved Xanthophylls esters as clear solution on filtration, cleaning dissolved oleoresin comprising xanthophylls esters in ion-exchange resin, hydrolyzing the clear solution with base in presence of phase-transfer catalyst in alcohol medium, quenching the hydrolyzed solution in water maintaining acidic pH to obtain un-dissolved solids on filtration, dissolving the solids in ester to obtain ester layer on filtration, drying ester layer to obtain semi-solid residue, triturating the semi-solid residue in alcohol whereby obtaining lutein crystals of about 65% assay and an alcoholic fraction, distilling the alcoholic fraction to obtain non water-soluble fractions, and mixing the Lutein crystals with non water-soluble fractions to obtain a stable Lutein paste.
Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
-
, (2008/06/13)
A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.
Carotenoid ester analogs or derivatives for controlling connexin 43 expression
-
, (2008/06/13)
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
